These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31512166)

  • 1. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.
    Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR: History and perspectives to the future.
    Kozovska Z; Rajcaniova S; Munteanu P; Dzacovska S; Demkova L
    Biomed Pharmacother; 2021 Sep; 141():111917. PubMed ID: 34328110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
    Mills EM; Barlow VL; Luk LYP; Tsai YH
    Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cas9 Ribonucleoprotein Complex Delivery: Methods and Applications for Neuroinflammation.
    Campbell LA; Richie CT; Maggirwar NS; Harvey BK
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):565-577. PubMed ID: 31172397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).
    Rodríguez-Rodríguez DR; Ramírez-Solís R; Garza-Elizondo MA; Garza-Rodríguez ML; Barrera-Saldaña HA
    Int J Mol Med; 2019 Apr; 43(4):1559-1574. PubMed ID: 30816503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Broad Application of CRISPR Cas9 in Infectious, Inflammatory and Neurodegenerative Diseases.
    Pahan K
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):534-536. PubMed ID: 31782056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
    Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs.
    Stahl EC; Sabo JK; Kang MH; Allen R; Applegate E; Kim SE; Kwon Y; Seth A; Lemus N; Salinas-Rios V; Soczek KM; Trinidad M; Vo LT; Jeans C; Wozniak A; Morris T; Kimberlin A; Foti T; Savage DF; Doudna JA
    Mol Ther; 2023 Aug; 31(8):2422-2438. PubMed ID: 37403358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid genome editing by CRISPR-Cas9-POLD3 fusion.
    Reint G; Li Z; Labun K; Keskitalo S; Soppa I; Mamia K; Tolo E; Szymanska M; Meza-Zepeda LA; Lorenz S; Cieslar-Pobuda A; Hu X; Bordin DL; Staerk J; Valen E; Schmierer B; Varjosalo M; Taipale J; Haapaniemi E
    Elife; 2021 Dec; 10():. PubMed ID: 34898428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
    Jiang C; Meng L; Yang B; Luo X
    Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.